Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel bought 2,000 shares of the firm's stock in a transaction that occurred on Friday, December 9th. The stock was bought at an average price of $13.11 per share, for a total transaction of $26,220.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,724,886 shares in the company, valued at $35,723,255.46. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Snehal Patel also recently made the following trade(s):

• On Friday, December 2nd, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $13.84 per share, for a total transaction of $13,840.00.
• On Wednesday, November 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $8.79 per share, for a total transaction of $17,580.00.
• On Friday, October 14th, Snehal Patel bought 3,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $9.75 per share, for a total transaction of $29,250.00.
• On Friday, October 7th, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $9.72 per share, with a total value of $19,440.00.
• On Friday, October 7th, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $9.72 per share, with a total value of $19,440.00.
• On Thursday, September 29th, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $9.23 per share, with a total value of $9,230.00.

Greenwich LifeSciences Stock Down 1.2 %

Shares of Greenwich LifeSciences stock opened at $12.97 on Friday. The stock has a market cap of $166.33 million, a PE ratio of -22.75 and a beta of 0.81. The business has a fifty day simple moving average of $11.04 and a 200-day simple moving average of $9.71. Greenwich LifeSciences, Inc. has a 12 month low of $6.82 and a 12 month high of $30.79.

Institutional Trading of Greenwich LifeSciences

Institutional investors have recently bought and sold shares of the company. Walleye Capital LLC acquired a new stake in Greenwich LifeSciences during the second quarter valued at $90,000. Goldman Sachs Group Inc. acquired a new stake in shares of Greenwich LifeSciences in the second quarter worth about $104,000. Bank of America Corp DE lifted its position in shares of Greenwich LifeSciences by 100.2% in the first quarter. Bank of America Corp DE now owns 6,213 shares of the company's stock worth $122,000 after buying an additional 3,110 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Greenwich LifeSciences in the second quarter worth about $130,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Greenwich LifeSciences in the second quarter worth about $150,000. Institutional investors and hedge funds own 8.06% of the company's stock.

About Greenwich LifeSciences

(Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Further Reading

• Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
• Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
• This is no Time to Buy Lennar but the Time is Coming
• Game-Changing News For Mullen Automotive
• Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
• Is Enterprise Products Partners Fairly Valued?

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.